PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Diflucortolone→

Diflucortolone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2607-06-9
Molecular formula
C22H28F2O4
Molecular weight
394.5 g/mol
Drug class
Topical glucocorticoidcorticosteroid receptor agonist
Mechanism of action
Activates intracellular glucocorticoid receptors in skin, regulating inflammatory gene expression and suppressing cytokine production, leukocyte migration and other immune responses.
Indications / reported uses
  • Topical treatment of corticosteroid-responsive inflammatory dermatoses, including eczema and dermatitis, using the appropriate strength and formulation; combination products containing an antifungal have separate combination-specific indications

Sources: UK product information — Diflucortolone-containing products · NLM MeSH — Diflucortolone · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Diflucortolone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Diflucortolone Permitted Daily Exposure (PDE) report (the Diflucortolone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Diflucortolone Occupational Exposure Limit (OEL) report (the Diflucortolone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.